-
The basic demographic characteristics of subjects included age, sex, height, and weight. In the discovery study, all of the data in three groups conformed to a normal distribution, and no statistical differences existed among groups. In the validation study,
the basic characteristics in three groups were not normally distributed (P < 0.05) because there were fewer subjects in the internal control and case groups. The basic characteristics of children were shown in Table 1. Table 1. The demographic characteristics of subjects in two-stage study
Cohort Indexes External control group Internal control group Case group Discovery cohort* Total number 50 51 56 Sex (male/female) 28/22 30/21 25/31 Age (years) 12.5 ± 1.09 12.09 ± 1.21 12.24 ± 1.55 Height (cm) 142.68 ± 6.84 141.63 ± 6.19 142.89 ± 6.26 Weight (kg) 34.36 ± 5.22 33.84 ± 4.83 34.50 ± 4.96 Validation cohort# Total number 50 41 31 Sex (male/female) 25/25 24/17 14/17 Age (years) 10.0 (8.0, 10.0) 11.0 (10.0, 12.0) 12.0 (10.0, 13.0) Height (cm) 129.5 (122.2, 135.0) 136.0 (129.0, 140.0) 137.0 (132.5, 154.5) Weight (kg) 26.0 (23.0, 29.0) 30.5 (26.0, 35.0) 32.0 (25.5, 39.5) Note. *The age, height and weight of the subjects in the three groups all followed the normal distribution and had the same variance, with no statistical difference (P > 0.05). #The age, height and weight of the three groups were not subject to normal distribution, with statistically significant differences (P < 0.05). -
The detection stage in serum identified 7,064 metabolites and 1,879 metabolites with VIP > 1. Using non-parametric tests, 1,384 metabolites with statistical significance among three groups (P < 0.05) were selected. By searching online databases (Metlin and HMDB), eight endogenous metabolites potentially closely associated with KBD were discovered, namely, kynurenic acid, N-α-acetylarginine, 6-hydroxymelatonin, sphinganine, ceramide, sphingosine-1P, spermidine, and glycine. The details of metabolites can be seen in Table 2.
Table 2. Endogenous difference metabolites in serum associated with KBD selected in discovery study
Metabolites m/z (Da) RT (min) VIP Variation trends P value Kynurenic acid 190.084 4.526 2.492 + < 0.0001 N-α-acetylarginine 217.098 1.626 1.573 − 0.0040 6-hydroxymelatonin 249.158 14.695 1.578 − < 0.0001 Sphinganine 302.306 1.056 2.596 − < 0.0001 Ceramide 330.332 16.913 1.935 + < 0.0001 Glycine 362.241 8.784 2.835 − < 0.0001 Sphingosine 1-phosphate 394.232 19.232 2.318 − < 0.0001 Spermidine 674.258 10.697 1.907 + 0.0010 Note. +: The metabolite level of the case group was higher than that of the control groups; -: The metabolite level of the case group was lower than that of the external control group. -
Except for ceramide, seven substances selected in the discovery study were determined by HPLC-Q-TRAP-MS. Five candidate metabolites were validated and they were kynurenic acid, N-α-acetylarginine, sphinganine, spermidine, and sphingosine-1P. The levels of these substances and statistical analysis results are shown in Table 3. With the exception of spermidine, the other four substances showed low expression in the case group. Between the two control groups, with the exception of sphinganine the levels of the other four substances showed higher expression in the internal control group. The details are presented in Figure 2.
Table 3. Verified difference metabolites and the level among three groups in validation cohort (ng/mL)
Metabolites External control group Internal control group Case group P value Kynurenic acid* 1.60 (0.97, 2.18)a 2.82 (1.90, 4.32)b 1.15 (0.68, 1.81)a < 0.0001 N-α-Acetylarginine 28.41 ± 17.12a 47.36 ± 19.57b 19.98 ± 9.17a < 0.0001 Sphinganine 8.22 ± 2.43a 6.94 ± 2.37ab 6.20 ± 2.05b 0.0240 Spermidine* 19.20 (14.78, 29.38)a 43.70 (35.38, 67.48)b 30.10 (21.00, 50.53)b < 0.0001 Sphingosine 1P 709.25 ± 149.73a 799.30 ± 139.61a 591.75 ± 115.31b < 0.0001 Note. *The data did not conform to the normal distribution and was described by the median (quartile); other data conformed to normal distribution, expressed as mean ± standard deviation. a and b represented statistically significant among case group, external control group and internal control group, respectively, different letter means difference and one same letter means no-difference. -
An ROC curve was constructed in order to evaluate the potential of single metabolites validated in the second cohort for disease recognition. The results were as follows: between the internal control group and case group, the AUC of kynurenic acid, N-α-acetylarginine, sphinganine, spermidine, and sphingosine-1P was 0.85, 0.88, 0.58, 0.66, and 0.87, respectively; between the external control group and case group, the AUC of five metabolites was 0.63, 0.64, 0.74, 0.74, and 0.75, respectively; between the two control groups, the AUC of five metabolites was 0.78, 0.75, 0.67, 0.87, and 0.67, respectively. Details are shown in Figure 3.
-
In this study, the metabolic pathways in which the eight metabolites found in the discovery study were identified and analyzed. Results showed that these metabolites were mainly involved in three metabolic pathways, namely sphingolipid metabolism, glutathione metabolism and tryptophan metabolism, in which, the impact value of sphingolipid metabolism was maximal (up to 0.46; Table 4). The sphingolipid metabolism pathway included sphinganine, ceramide, and sphingosine-1P; the glutathione metabolism pathway included spermidine and glycine; and kynurenic acid and 6-hydroxymelatonin were included in the tryptophan metabolism pathway.
Table 4. The results of metabolic pathways analysis
Pathways Total Hits Raw P -Log (P) Holm adjust P FDR PI Sphingolipid metabolism 25 3 0.0010 6.9000 0.08 0.08 0.4602 Glutathione metabolism 38 2 0.0386 3.2600 1.00 0.91 0.0361 Tryptophan metabolism 79 3 0.0259 3.6500 1.00 0.91 0.0114 Note. Total means the total number of compounds in the pathway; Hits means the number of actual matches between the input metabolites and the compounds in the pathway; Raw P is the original P value derived from the enrichment analysis and < 0.05 means significance; PI means the impact factor of the pathway, which is obtained through topological analysis and it is significant when PI > 0.01.
doi: 10.3967/bes2020.100
Serum Metabolomic Indicates Potential Biomarkers and Metabolic Pathways of Pediatric Kashin-Beck Disease
-
Abstract:
Objective To explore potential serum biomarkers of children with Kashin-Beck Disease (KBD) and the metabolic pathways to which the biomarkers belong. Methods A two-stage metabolomic study was employed. The discovery cohort included 56 patients, 51 internal controls, and 50 external controls. The metabolites were determined by HPLC-(Q-TOF)-MS and confirmed by Human Metabolome Databases (HMDB) and Metlin databases. MetaboAnalyst 3.0 and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database were used to analyze the metabolic pathways of the candidate metabolites. The use of HPLC-(Q-TRAP)-MS enabled quantitative detection of the target metabolites which were chosen using the discovery study and verified in another independent verification cohort of 31 patients, 41 internal controls, and 50 external controls. Results Eight candidate metabolites were identified out in the discovery study, namely kynurenic acid, N-α-acetylarginine, 6-hydroxymelatonin, sphinganine, ceramide, sphingosine-1P, spermidine, and glycine. These metabolites exist in sphingolipid, glutathione, and tryptophan metabolic pathways. In the second-stage study, five candidate metabolites were validated, including kynurenic acid, N-α-acetylarginine, sphinganine, spermidine, and sphingosine-1P. Except for spermidine, all substances exhibited low expression in the case group compared with the external control group, and the difference in levels of sphinganine, spermidine, and sphingosine-1P was statistically significant. Conclusion The direction of change of levels of sphinganine, spermidine, and sphingosine-1P in the two-stage study cohorts was completely consistent, and the differences were statistically significant. Therefore, these substances can be used as potential biomarkers of KBD. Furthermore, these results raise the possibility that sphingolipid metabolic pathways may be closely related to KBD. -
Key words:
- Kashin-Beck disease /
- Potential biomarkers /
- Metabolism pathways /
- Serum
注释: -
Table 1. The demographic characteristics of subjects in two-stage study
Cohort Indexes External control group Internal control group Case group Discovery cohort* Total number 50 51 56 Sex (male/female) 28/22 30/21 25/31 Age (years) 12.5 ± 1.09 12.09 ± 1.21 12.24 ± 1.55 Height (cm) 142.68 ± 6.84 141.63 ± 6.19 142.89 ± 6.26 Weight (kg) 34.36 ± 5.22 33.84 ± 4.83 34.50 ± 4.96 Validation cohort# Total number 50 41 31 Sex (male/female) 25/25 24/17 14/17 Age (years) 10.0 (8.0, 10.0) 11.0 (10.0, 12.0) 12.0 (10.0, 13.0) Height (cm) 129.5 (122.2, 135.0) 136.0 (129.0, 140.0) 137.0 (132.5, 154.5) Weight (kg) 26.0 (23.0, 29.0) 30.5 (26.0, 35.0) 32.0 (25.5, 39.5) Note. *The age, height and weight of the subjects in the three groups all followed the normal distribution and had the same variance, with no statistical difference (P > 0.05). #The age, height and weight of the three groups were not subject to normal distribution, with statistically significant differences (P < 0.05). Table 2. Endogenous difference metabolites in serum associated with KBD selected in discovery study
Metabolites m/z (Da) RT (min) VIP Variation trends P value Kynurenic acid 190.084 4.526 2.492 + < 0.0001 N-α-acetylarginine 217.098 1.626 1.573 − 0.0040 6-hydroxymelatonin 249.158 14.695 1.578 − < 0.0001 Sphinganine 302.306 1.056 2.596 − < 0.0001 Ceramide 330.332 16.913 1.935 + < 0.0001 Glycine 362.241 8.784 2.835 − < 0.0001 Sphingosine 1-phosphate 394.232 19.232 2.318 − < 0.0001 Spermidine 674.258 10.697 1.907 + 0.0010 Note. +: The metabolite level of the case group was higher than that of the control groups; -: The metabolite level of the case group was lower than that of the external control group. Table 3. Verified difference metabolites and the level among three groups in validation cohort (ng/mL)
Metabolites External control group Internal control group Case group P value Kynurenic acid* 1.60 (0.97, 2.18)a 2.82 (1.90, 4.32)b 1.15 (0.68, 1.81)a < 0.0001 N-α-Acetylarginine 28.41 ± 17.12a 47.36 ± 19.57b 19.98 ± 9.17a < 0.0001 Sphinganine 8.22 ± 2.43a 6.94 ± 2.37ab 6.20 ± 2.05b 0.0240 Spermidine* 19.20 (14.78, 29.38)a 43.70 (35.38, 67.48)b 30.10 (21.00, 50.53)b < 0.0001 Sphingosine 1P 709.25 ± 149.73a 799.30 ± 139.61a 591.75 ± 115.31b < 0.0001 Note. *The data did not conform to the normal distribution and was described by the median (quartile); other data conformed to normal distribution, expressed as mean ± standard deviation. a and b represented statistically significant among case group, external control group and internal control group, respectively, different letter means difference and one same letter means no-difference. Table 4. The results of metabolic pathways analysis
Pathways Total Hits Raw P -Log (P) Holm adjust P FDR PI Sphingolipid metabolism 25 3 0.0010 6.9000 0.08 0.08 0.4602 Glutathione metabolism 38 2 0.0386 3.2600 1.00 0.91 0.0361 Tryptophan metabolism 79 3 0.0259 3.6500 1.00 0.91 0.0114 Note. Total means the total number of compounds in the pathway; Hits means the number of actual matches between the input metabolites and the compounds in the pathway; Raw P is the original P value derived from the enrichment analysis and < 0.05 means significance; PI means the impact factor of the pathway, which is obtained through topological analysis and it is significant when PI > 0.01. -
[1] Cao J, Li S, Shi Z, et al. Articular cartilage metabolism in patients with Kashin-Beck disease: an endemic osteoarthropathy in China. Osteoarthritis Cartilage, 2008; 16, 680−8. doi: 10.1016/j.joca.2007.09.002 [2] Pasteels J, Liu FD, Hinsenkamp M, et al. Histology of kashin-beck lesions. Int Orthop, 2001; 25, 151−3. doi: 10.1007/s002640000190 [3] Yang JB. The instance sequence of research report on the etiology of KBD. Chin J End Dis Prevent Ctrl, 1997; 12, 183−6. (In Chinese) [4] Sun L, Meng F, Li Q, et al. Effects of the consumption of rice from non-KBD areas and selenium supplementation on the prevention and treatment of paediatric Kaschin-Beck disease: an epidemiological intervention trial in the Qinghai Province. Osteoarthritis Cartilage, 2014; 22, 2033−40. doi: 10.1016/j.joca.2014.09.013 [5] Dong W, Zhang Y, Liu H, et al. Detection of unsaturated disaccharides, pyridinoline, and hydroxyproline in urine of patients with Kashin-Beck disease: comparison with controls in an endemic area. J Rheumatol, 2009; 36, 816−21. doi: 10.3899/jrheum.080642 [6] Zhao X, Fritsche J, Wang J, et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics, 2010; 6, 362−74. doi: 10.1007/s11306-010-0203-1 [7] Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev, 2007; 26, 51−78. doi: 10.1002/mas.20108 [8] Connor SC, Hansen MK, Corner A, et al. Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol Biosyst, 2010; 6, 909−21. doi: 10.1039/b914182k [9] National Kashin-Beck Disease Surveillance Group. Report of a national survey of Kashin-Beck Disease prevalence in 2005. Chin J Epidemiol, 2006; 25, 670−2. (In Chinese) [10] National Kashin-Beck Disease Surveillance Group. Report of a national survey of Kashin-Beck Disease prevalence in 2006. Chin J Epidemiol, 2007; 26, 646−8. (In Chinese) [11] Ministry of Health of the People’s Republic of China Document: Guidelines for Health. Diagnosis of Kashin-Beck Disease. Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention.; 2010: (WS/T 207-2010). (In Chinese) [12] Ke CP, Zhang T, Wu XY, et al. Statistical methods for metabolomics data analysis. Chin J Health Stats, 2014; 31, 357−65. (In Chinese) [13] MacRae V, Burdon T, Ahmed S, et al. Ceramide inhibition of chondrocyte proliferation and bone growth is IGF-I independent. J Endocrinol, 2006; 191, 369−77. doi: 10.1677/joe.1.06958 [14] Li S, Cao J, Caterson B, et al. Proteoglycan metabolism, cell death and Kashin-Beck disease. Glycoconj J, 2012; 29, 241−8. doi: 10.1007/s10719-012-9421-2 [15] Nap RJ, Szleifer I. Structure and interactions of aggrecans: statistical thermodynamic approach. Biophys J, 2008; 95, 4570−83. doi: 10.1529/biophysj.108.133801 [16] Tang X, Zhou Z, Shen B, et al. Serum levels of TNF-α, IL-1β, COMP, and CTX-II in patients with Kashin-Beck disease in Sichuan, China. Rheumatol Int, 2012; 32, 3503−9. doi: 10.1007/s00296-011-2172-8 [17] Hait NC, Oskeritzian CA, Paugh SW, et al. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta, 2006; 1758, 2016−26. doi: 10.1016/j.bbamem.2006.08.007 [18] Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol, 2004; 15, 513−20. [19] Stanic I, Facchini A, Borzì RM, et al. Polyamine depletion inhibits apoptosis following blocking of survival pathways in human chondrocytes stimulated by tumor necrosis factor-α. J Cell Physiol, 2006; 206, 138−46. doi: 10.1002/jcp.20446 [20] Facchini A, BorzÍ RM, Marcu KB, et al. Polyamine depletion inhibits NF-κB binding to DNA and interleukin-8 production in human chondrocytes stimulated by tumor necrosis factor-α. J Cell Physiol, 2005; 204, 956−63. doi: 10.1002/jcp.20368 [21] Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest, 2006; 116, 3150−9. doi: 10.1172/JCI29463 [22] Takahashi N, Udagawa N, Suda T. Vitamin D endocrine system and osteoclasts. Bonekey Rep, 2014; 3, 495. [23] Sabatini M, Rolland G, Léonce S, et al. Effects of ceramide on apoptosis, proteoglycan degradation, and matrix metalloproteinase expression in rabbit articular cartilage. Biochem Biophys Res Commun, 2000; 267, 438−44. doi: 10.1006/bbrc.1999.1983